Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

Introduction: Treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and myeloid sarcoma (MS) has presented challenges for decades. Studies on selinexor in combination with various standard or intensive chemotherapy regimens for the treatment of R/R AML have demonstrated promising resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Xiwen, Jin, Jie, Xu, Bin, Su, Shuai, Li, Li, Li, Mengyuan, Peng, Yizhou, Mao, Xia, Huang, Wei, Zhang, Donghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436481/
https://www.ncbi.nlm.nih.gov/pubmed/37601075
http://dx.doi.org/10.3389/fphar.2023.1217701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436481/
https://www.ncbi.nlm.nih.gov/pubmed/37601075
http://dx.doi.org/10.3389/fphar.2023.1217701

Ejemplares similares